Mural Oncology (NASDAQ:MURA) Stock Rating Lowered by Raymond James

Raymond James cut shares of Mural Oncology (NASDAQ:MURA) from a strong-buy rating to an outperform rating in a research report sent to investors on Tuesday, MarketBeat.com reports. Raymond James currently has $18.00 price target on the stock.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Mural Oncology in a research note on Wednesday, March 12th. Jones Trading reissued a “hold” rating on shares of Mural Oncology in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.00.

Mural Oncology Price Performance

NASDAQ MURA opened at $1.47 on Tuesday. Mural Oncology has a 1-year low of $1.37 and a 1-year high of $5.12. The stock has a market capitalization of $25.33 million, a price-to-earnings ratio of -0.16 and a beta of 3.66. The business’s fifty day moving average price is $3.87 and its 200-day moving average price is $3.61.

Mural Oncology (NASDAQ:MURA) last announced its earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period in the prior year, the company earned ($3.57) earnings per share. Equities research analysts anticipate that Mural Oncology will post -7.54 EPS for the current year.

Institutional Investors Weigh In On Mural Oncology

Several institutional investors and hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC boosted its position in shares of Mural Oncology by 1.4% during the fourth quarter. Squarepoint Ops LLC now owns 175,502 shares of the company’s stock worth $565,000 after acquiring an additional 2,470 shares during the last quarter. Two Sigma Advisers LP purchased a new stake in Mural Oncology in the 4th quarter worth $84,000. Two Sigma Investments LP boosted its holdings in shares of Mural Oncology by 12.0% during the 4th quarter. Two Sigma Investments LP now owns 65,150 shares of the company’s stock valued at $210,000 after purchasing an additional 6,993 shares during the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Mural Oncology during the 4th quarter valued at about $94,000. Finally, Acorn Capital Advisors LLC purchased a new position in shares of Mural Oncology during the fourth quarter valued at about $4,141,000. Institutional investors own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.